Luton, Bedfordshire, United Kingdom, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Exactitude Consultancy, the market research and consulting wing of Ameliorate Digital Consultancy Private Limited has completed and published the final copy of the detailed research report on the Chronic Obstructive Pulmonary Disease Drug Market.
In 2022, the chronic obstructive pulmonary disease segment holds the largest market share. Moreover, the same segment is expected to register the highest CAGR from 2022 to 2029
One of the main reasons propelling the growth of the chronic obstructive pulmonary disease (COPD) Drug market is the increase in the prevalence of chronic obstructive pulmonary disease (COPD) among the population worldwide. The rise in demand for pharmaceuticals to treat breathing difficulties, coughs, mucus production, and wheezing, as well as the comfort and ease of home care therapies and treatments for chronic respiratory diseases, are driving the expansion of the chronic obstructive pulmonary disease (COPD) drug market. The market for drugs to treat chronic obstructive pulmonary disease (COPD) is further impacted by the growing knowledge of respiratory disorders, their treatments, and the precautions that go along with them.
Chronic Obstructive Pulmonary Disease Drug Market Key Players
Chronic Obstructive Pulmonary Disease Drug Market Major Key Players include: - AstraZeneca, Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, Novartis AG, Teva Pharmaceutical Industries Ltd., Sunovion Pharmaceuticals Inc. (Sumitomo Dainippon Pharma Co., Ltd.), CHIESI Farmaceutici S.p.A., Orion Corporation, Mylan N.V., Others.
Get Access to sample Report Pages for Chronic Obstructive Pulmonary Disease Drug Market
Rising Interest in Chronic Obstructive Pulmonary Disease Drug to Promote Growth
Growing regional government programmes have enhanced animal healthcare and raised demand for veterinary immunizations. For instance, the Food and Agriculture Organization of the United Nations (FAO) and the Ministry of Fisheries and Livestock helped the Kwilu and Kwango districts of the Democratic Republic of the Congo introduce a cow immunization programme in 2019.
Additionally, as the number of animals has grown, so has interest worldwide in effective systems for tracking animal health. According to FAO, animal production makes up around 40% of all agricultural output worldwide.
Chronic Obstructive Pulmonary Disease Drug Market: Recent Development
- The FDA advisory group decided against approving GSK's mepolizumab (Nucala) as an additional COPD therapy in July 2018.
- Innoviva and GSK collaborated to develop TRELEGY ELLIPTA, which the U.S. FDA authorised for use in patients with COPD in September 2017.
- SPIRIVA RESPIMAT from Boehringer Ingelheim was approved by the US FDA in September 2014 for the long-term treatment of COPD-related bronchospasm.
- Bevespi Aerosphere (glycopyrronium/formoterol fumarate), developed by AstraZeneca, was approved by the European Commission in January 2019. It is intended for people with COPD.
| Report Metric | Details |
| Base Year Considered | 2021 |
| Forecast Period | 2022-2029 |
| Forecast Unit | Value (USD) |
| Segments Covered | Drug Class, Distribution Channel, and Region |
| Regions Covered | North America, Europe, Asia-Pacific, and LAMEA |
| Companies Covered | AstraZeneca, Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, Novartis AG, Teva Pharmaceutical Industries Ltd., Sunovion Pharmaceuticals Inc. (Sumitomo Dainippon Pharma Co., Ltd.), CHIESI Farmaceutici S.p.A., Orion Corporation, Mylan N.V., Others. |
Browse Complete Premium Report for Chronic Obstructive Pulmonary Disease Drug Market:
Chronic Obstructive Pulmonary Disease Drug Market Segmentation
By Drug Class, it is segmented into
- Combination Therapy
- Triple Therapy
- Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
- Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
- Others
- Corticosteroids
- Phosphodiesterase Type 4 Inhibitors
- Mucokinetics
- Bronchodilators
- Long Acting Beta Agonist (LABA)
- Short Acting Beta Agonist (SABA)
- Long Acting Muscarinic Antagonist (LAMA)
- Others
By Distribution Channel is segmented into
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Chronic Obstructive Pulmonary Disease Drug Market – Drivers and Restraints
- LAMA-ICS, LABA-ICS, triple treatment, and other combination medications are examples of combination therapy.
- Combination treatment is becoming more popular since it is more efficient than using a bronchodilator and a corticosteroid separately.
- The market for treating chronic obstructive pulmonary disease is anticipated to grow as more patients who were not responding to bronchodilators or corticosteroids are being effectively treated with combination therapy.
- For treating the symptoms and quality of life of chronic obstructive pulmonary disease, combination treatment is superior than monotherapy.
Chronic Obstructive Pulmonary Disease Drug Market: Regional Analysis
A sedentary lifestyle, fast urbanization, and exponentially rising air pollution are all factors that will cause North America to dominate the worldwide market for COPD medications. Additionally, it is anticipated that an increase in the smoking rate and a lack of knowledge about COPD would increase the disease's prevalence and lead to a rise in the use of COPD medications. In Canada, COPD is the fourth most common cause of hospitalization for men and the sixth most common for women, according to The Lung Association.
Chronic Obstructive Pulmonary Disease Drug Market: Top Impacting Factors
- There are 251 million cases of COPD worldwide, according to the Institute of Health Metrics and Evaluation's Global Burden of Disease Study from 2016.
- Around 200 million people had COPD diagnoses worldwide in 2016, according to WHO. Urbanization exposes people to a variety of lung irritants that may be a significant risk factor for COPD in emerging nations in the Asia Pacific region.
- According to the World Health Organization (WHO), second- and first-hand smoking exposure is the most frequent cause of COPD. During the projected period, the rising incidence of COPD is anticipated to fuel market expansion for COPD medications.
Browse More Pharmaceutical Market Reports by Pharma Research Consulting
Tumor Lysis Syndrome Treatment Market
Having a tumour causes a disease known as tumour lysis syndrome (TLS). The market report offers a comprehensive analysis of the current market situation, covering past and future market sizes based on technological advancement, value, and volume, as well as factors that are both cost-effective and market-leading.
Tumor-induced Osteomalacia Market
An uncommon paraneoplastic bone disorder called oncogenic osteomalacia, also known as tumor-induced osteomalacia, is characterised by osteomalacia or rickets brought on by a phosphaturic mesenchymal tumour (PMT). To identify tumor-induced osteomalacia, elevated levels of blood phosphate, vitamin D-regulating hormone, and fibroblast growth factor 23 (FGF23) were employed. According to a research done at Maastricht University Hospital, 8% of cancer patients have the paraneoplastic syndrome.
Sterile Active Pharmaceutical Ingredients Market
Any combination of chemicals or material intended for use in the creation of a medication or therapeutic product is referred to as a pharmaceutical ingredient. This chemical becomes the drug's active component when it is employed in the production of medication. These elements are created to carry out pharmacological activities or have another direct impact on the mitigation, cure, diagnosis, or treatment of a disease. Additionally, it can directly affect how the body works and how it is built. According to the report, the market for sterile active pharmaceutical ingredients will rise quickly due to the product's increasing importance.
Athletic Knee Treatment Market
The early training cycle of an athlete is when pull strains or muscles are more common. The likelihood of having recurring or chronic knee pain is highest in young athletes. The most prevalent knee condition among athletes is patellofemoral pain syndrome. Young athletes are increasingly seeking therapy in primary care or general practise settings for knee problems.
